BRPI0508813B8 - vacinas líquidas de combinação com baixa dose de conjugado de hib - Google Patents

vacinas líquidas de combinação com baixa dose de conjugado de hib

Info

Publication number
BRPI0508813B8
BRPI0508813B8 BRPI0508813A BRPI0508813A BRPI0508813B8 BR PI0508813 B8 BRPI0508813 B8 BR PI0508813B8 BR PI0508813 A BRPI0508813 A BR PI0508813A BR PI0508813 A BRPI0508813 A BR PI0508813A BR PI0508813 B8 BRPI0508813 B8 BR PI0508813B8
Authority
BR
Brazil
Prior art keywords
low dose
hib
hib conjugate
combination liquid
conjugate
Prior art date
Application number
BRPI0508813A
Other languages
English (en)
Inventor
Contorni Mario
Original Assignee
Chiron Srl
Gsk Vaccines S R L
Novartis Vaccines And Diagnostics S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32117706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508813(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Srl, Gsk Vaccines S R L, Novartis Vaccines And Diagnostics S R L filed Critical Chiron Srl
Publication of BRPI0508813A publication Critical patent/BRPI0508813A/pt
Publication of BRPI0508813B1 publication Critical patent/BRPI0508813B1/pt
Publication of BRPI0508813B8 publication Critical patent/BRPI0508813B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

vacinas de combinação com baixa dose de conjugado de hib vacinas de combinação incluindo antígenos para imunizar contra difteria, tétano, coqueluche e hib são conhecidas (vacinas "dtp-hib" ). a invenção está direcionada à necessidade por tais vacina com baixas doses de antígeno de hib, para reduzir custos, que não requerem reconstituição no campo. assim, a invenção fornece uma vacina de combinação compreendendo antígenos para proteger um indivíduo contra pelo menos difteria, tétano, coqueluche e hib, onde: (a) o antígeno para proteger contra hib é um conjugado de um sacarídeo capsular de hib; (b) a concentração do conjugado de hib na vacina é < 15 (mi)g/ml; e (c) o conjugado de hib nunca foi liofilizado. descobriu-se que as vacinas da invenção são seguras e altamente imunogênicas.
BRPI0508813A 2004-03-15 2005-03-14 vacinas líquidas de combinação com baixa dose de conjugado de hib BRPI0508813B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0405787.3A GB0405787D0 (en) 2004-03-15 2004-03-15 Low dose vaccines
GB0405787.3 2004-03-15
PCT/IB2005/000927 WO2005089794A2 (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate

Publications (3)

Publication Number Publication Date
BRPI0508813A BRPI0508813A (pt) 2007-08-07
BRPI0508813B1 BRPI0508813B1 (pt) 2019-05-21
BRPI0508813B8 true BRPI0508813B8 (pt) 2021-05-25

Family

ID=32117706

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508813A BRPI0508813B8 (pt) 2004-03-15 2005-03-14 vacinas líquidas de combinação com baixa dose de conjugado de hib

Country Status (13)

Country Link
US (2) US20090208526A1 (pt)
EP (1) EP1725258B1 (pt)
JP (2) JP4954056B2 (pt)
CN (2) CN102028944B (pt)
AT (1) ATE480257T1 (pt)
BR (1) BRPI0508813B8 (pt)
CA (1) CA2559996C (pt)
DE (1) DE602005023422D1 (pt)
DK (1) DK1725258T3 (pt)
GB (1) GB0405787D0 (pt)
RU (1) RU2435609C2 (pt)
SG (1) SG151253A1 (pt)
WO (1) WO2005089794A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000198A (es) * 2000-06-29 2004-09-13 Glaxosmithkline Biolog Sa Composicion de vacuna multivalente.
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
HUE031380T2 (en) 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines
PT2066344E (pt) 2006-09-07 2011-07-05 Glaxosmithkline Biolog Sa Vacina de combinação de poliovírus inactivado
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
CN102066401A (zh) 2008-05-01 2011-05-18 艾瑞克有限公司 蛋白质制品
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
WO2011074006A2 (en) * 2009-12-16 2011-06-23 Serum Institute Of India Ltd. Vaccine composition
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
AU2012245198B2 (en) * 2011-04-21 2017-07-13 Trustees Of Tufts College Compositions and methods for stabilization of active agents
WO2013132041A2 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
US20150297714A1 (en) * 2012-10-29 2015-10-22 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
WO2018074296A1 (ja) * 2016-10-20 2018-04-26 一般財団法人化学及血清療法研究所 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
EA202090316A1 (ru) 2017-07-18 2020-12-08 Серум Инститьют Оф Индия Пвт Лтд. Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее получения
CN110251667A (zh) * 2018-05-11 2019-09-20 武汉博沃生物科技有限公司 一种免疫组合制剂及其制备方法和应用
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
BRPI9609414B8 (pt) * 1995-06-23 2021-05-25 Smithkline Beecham Biologicals S A combinação de vacina e kit para produzir a mesma.
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
MXPA03000198A (es) 2000-06-29 2004-09-13 Glaxosmithkline Biolog Sa Composicion de vacuna multivalente.

Also Published As

Publication number Publication date
ATE480257T1 (de) 2010-09-15
JP2007529503A (ja) 2007-10-25
GB0405787D0 (en) 2004-04-21
EP1725258A2 (en) 2006-11-29
BRPI0508813B1 (pt) 2019-05-21
JP4954056B2 (ja) 2012-06-13
CA2559996A1 (en) 2005-09-29
US9259460B2 (en) 2016-02-16
WO2005089794A2 (en) 2005-09-29
CN102028944B (zh) 2013-12-04
US20090208526A1 (en) 2009-08-20
CN1968711B (zh) 2011-01-05
DK1725258T3 (da) 2010-11-01
CN102028944A (zh) 2011-04-27
EP1725258B1 (en) 2010-09-08
SG151253A1 (en) 2009-04-30
RU2006136212A (ru) 2008-04-27
WO2005089794A3 (en) 2006-03-09
RU2435609C2 (ru) 2011-12-10
JP2008150397A (ja) 2008-07-03
US20120107346A1 (en) 2012-05-03
DE602005023422D1 (de) 2010-10-21
CN1968711A (zh) 2007-05-23
CA2559996C (en) 2014-08-05
BRPI0508813A (pt) 2007-08-07

Similar Documents

Publication Publication Date Title
BRPI0508813B8 (pt) vacinas líquidas de combinação com baixa dose de conjugado de hib
UY26801A1 (es) Composición de vacuna
DK1835939T3 (da) Meningokokkonjugatvaccination
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
MA30065B1 (fr) Vaccin
PE11298A1 (es) Vacunas
BRPI0510315A (pt) integração de vacinação com conjugado meningocócico
NO20015073D0 (no) Vaksiner
RU2009149359A (ru) Состав вакцин против менингита
RU2009134033A (ru) Жидкие вакцины для множественных серогрупп менингококков
BR9913446A (pt) Produtos de aglicona e métodos de uso
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
WO1999050303A3 (en) Immune response modulator alpha-2 macroglobulin complex
EE05474B1 (et) Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks
IL107387A (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. (IT)

B25D Requested change of name of applicant approved

Owner name: GSK VACCINES S.R.L. (IT)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF